Top

Cancer Chemotherapy and Pharmacology

Published in:

01-09-2019 | Polyneuropathy | Original Article

Electrophysiologic evaluation of facial nerve functions after oxaliplatin treatment

Authors: Oznur Yigit, Mavis Emel Kulak Kayikci, Cagri Mesut Temucin, Sarp Sarac, Mustafa Erman, Erol Belgin

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2019

Abstract

Purpose

This study analyzes the effect of oxaliplatin treatment on the facial nerve. The facial nerve is the most commonly paralyzed cranial motor nerve because it advances through a long, curved bone canal. Electroneurography and blink reflex are the electrophysiological measurements used for evaluating facial nerve function. Oxaliplatin is a cytotoxic agent used in adjuvant or palliative systemic therapy for colorectal cancer treatment.

Methods

This study was performed on 20 individuals who were at least 18 years old at Hacettepe University Ear Nose Throat Department, Audiology and Speech Disorders Unit, and Neurology Division EMG Laboratory as they received oxaliplatin treatment from Hacettepe University Oncology Hospital. Electroneurography and blink-reflex values were recorded and examined. The parameters taken during the second and fourth months were compared for this purpose.

Results

This study shows that the prolongation of distal latencies of compound muscle action potential is statistically significant, the amplitudes showed no difference. The ENoG results were analyzed, the prolongation of latency measurements between pre-treatment and the fourth month after treatment were statistically significant. The blink-reflex results showed that comparison with the baseline values, the prolongation of latencies in R1 measurements between pre-treatment, the second month, and the fourth month were significant.

Conclusions

The facial nerve is affected asymptomatically by oxaliplatin treatment. During oxaliplatin treatment, the evaluation of facial nerve function could be beneficial for patients by improving their quality of life. Electroneurography and blink-reflex tests can be used in the early evaluations of different medicines to determine their neurotoxicity.

Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249(1):9–17CrossRefPubMed

Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J et al (2013) Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol 25(2):398–403CrossRefPubMed

André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351CrossRefPubMed

Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C et al (2009) Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer. 9(1):347CrossRefPubMedPubMedCentral

Cersosimo RJ (2005) Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 39(1):128–135CrossRefPubMed

Esslen E. The acute facial palsies: investigations on the localization and pathogenesis of meato-labyrinthine facial palsies: Springer Science & Business Media; 2012

VanSwearingen JM, Cohn JF, Bajaj-Luthra A (1999) Specific impairment of smiling increases the severity of depressive symptoms in patients with facial neuromuscular disorders. Aesthetic Plast Surg 23(6):416–423CrossRefPubMed

Ardic FN, Ardic F, Topaloglu J, Öncel S, Uguz MZ, Topalogu D (1997) Electroneurography in the late period of Bell’s palsy. Acta Otolaryngol 117(3):325–328CrossRefPubMed

Lee KJ (2015) KJ Lee’s essential otolaryngology, 11th edn. McGraw-Hill Education, New York

10.

Ardic F, Ardic F, Topaloglu J, Öncel S, Uguz M, Topalogu D (1997) Electroneurography in the late period of Bell’s palsy. Acta Otolaryngol 117(3):325–328CrossRefPubMed

11.

Akkuzu B (2008) Fasiyal Sinir Hastalıklarında Muayene ve Tanı Teknikleri. Türkiye Klinikleri Kulak Burun Boğaz Özel Dergisi. 1(1):8

12.

Hall JWI. Nonauditory clinical neurophysiology. In: D. DS (ed). New handbook of auditory evoked responses. USA: Pearson Education; 2007

13.

Cruccu G, Deuschl G (2000) The clinical use of brainstem reflexes and hand-muscle reflexes. Clin Neurophysiol 111(3):371–387CrossRefPubMed

14.

Gültekin M, Boztaş G (2014) Türkiye kanser istatistikleri. Türkiye Halk Sağlığı Kurumu, Sağlık Bakanlığı, p 43

15.

Pasetto LM, D’Andrea MR, Rossi E, Monfardini S (2006) Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol/Hematol 59(2):159–168CrossRef

16.

Kannarkat G, Lasher EE, Schiff D (2007) Neurologic complications of chemotherapy agents. Curr Opin Neurol 20(6):719–725PubMed

17.

Griffith KA, Zhu S, Johantgen M, Kessler MD, Renn C, Beutler AS et al (2017) Oxaliplatin-induced peripheral neuropathy and identification of unique severity groups in colorectal cancer. J Pain Symptom Manag. 54(5):701-6. e1CrossRef

18.

Pulvers JN, Marx G (2017) Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review. Asia-Pac J Clin Oncol 13(6):345–355CrossRefPubMed

19.

Akkuzu B (2008) Fasiyal Sinir Hastalıklarında Muayene ve Tanı Teknikleri. Turkiye Klinikleri J Ear Nose Throat-Spec Topics. 1(1):8–13

20.

Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C (2000) The chemotherapeutic oxaliplatin alters voltage-gated Na + channel kinetics on rat sensory neurons. Eur J Pharmacol 406(1):25–32CrossRefPubMed

21.

Baba M, Fowler CJ, Jacobs JM, Gilliatt RW (1982) Changes in peripheral nerve fibres distal to a constriction. J Neurol Sci 54(2):197–208CrossRefPubMed

22.

Logician EL, Kelly JJ, Adelman LS (1994) Nerve conduction and biopsy correlation in over 100 consecutive patients with suspected polyneuropathy. Muscle Nerve 17(9):1010–1020CrossRef

23.

Feinberg DM, Preston DC, Shefner JM, Logigian EL (1999) Amplitude-dependent slowing of conduction in amyotrophic lateral sclerosis and polyneuropathy. Muscle Nerve 22(7):937–940CrossRefPubMed

24.

Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29(3):387–392CrossRefPubMed

25.

Kazem SS, Behzad D (2006) Role of blink reflex in diagnosis of subclinical cranial neuropathy in diabetic mellitus type II. Am J Phys Med Rehabil 85(5):449–452CrossRefPubMed

26.

Casale R, Frazzitta G, Fundarò C, Balbi P, Rosso AD, Bertinotti L et al (2004) Blink reflex discloses CNS dysfunction in neurologically asymptomatic patients with systemic sclerosis. Clin Neurophysiol 115(8):1917–1920CrossRefPubMed

27.

Cruccu G, Iannetti GD, Marx JJ, Thoemke F, Truini A, Fitzek S et al (2005) Brainstem reflex circuits revisited. Brain 128(2):386–394CrossRefPubMed

28.

Kimura J (1981) Conduction abnormalities of the facial and trigeminal nerves in polyneuropathy. Muscle Nerve 5(9S):S139–S144

Title: Electrophysiologic evaluation of facial nerve functions after oxaliplatin treatment
Authors: Oznur Yigit
Mavis Emel Kulak Kayikci
Cagri Mesut Temucin
Sarp Sarac
Mustafa Erman
Erol Belgin
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keyword: Polyneuropathy
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03841-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha

Identification of dinactin, a macrolide antibiotic, as a natural product-based small molecule targeting Wnt/β-catenin signaling pathway in cancer cells

The role of thioredoxin system in cancer: strategy for cancer therapy

Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study

The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients

A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer